ClinicalTrials.gg
TerminatedNCT04415073Updated Jul 22, 2022Results posted

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

A Phase 2 interventional study of SNDX-6352 and Placebo in Coronavirus, COVID and ARDS, sponsored by Syndax Pharmaceuticals. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-22.

Sponsored by Syndax Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
Given enrollment challenges, partly attributable to the constantly changing COVID-19 treatment landscape, the trial has been closed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 401 studies in Coronavirus Infections with a site in United States — 30 open to participants now, 40 under way, 7 of them phase 3. Coronavirus Infections · United States.

Enrollment
260th of 283
1 · median 94
Started
2020
with 251 others
Phase 2
90 of 401
4 open now
Registered
171st of 401
by date

Among the 401 studies in Coronavirus Infections with a site in United States, this one is the 260th largest by enrollment of the 283 interventional ones that give a count, is one of 252 that started in 2020, is one of 90 in phase 2, and was the 171st registered.

Coronavirus Infections

1,112 studies on the registry are indexed under Coronavirus Infections; 52 are open to participants now.

Browse Coronavirus Infections studies →

Open to participants now

30 of the 401 studies in Coronavirus Infections with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Coronavirus Infections studies recruiting now, 24 (60%) set no upper age limit and 9 (23%) stop at 75 or younger; 13 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in Coronavirus Infections with a site in United States, or all of them as a file.
02

Study summary

This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and symptoms secondary to COVID-19.

Read the detailed description

Axatilimab (SNDX-6352) is a humanized immunoglobin G4 monoclonal antibody with high affinity against colony stimulating factor-1 receptor (CSF-1R) under investigation for the prevention or treatment of respiratory signs and symptoms secondary to COVID-19.

This was a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of axatilimab as an add-on to SOC therapy in hospitalized participants with respiratory signs and symptoms secondary to COVID-19 compared to SOC treatment.

Eligible participants were to be randomized in a 1:1 ratio to 1 of 2 treatment groups, active or control. All participants were to receive axatilimab or matching placebo intravenously (IV) as an add-on to SOC on Day 1, within 8 hours of randomization and on Day 15. Participants were to be followed for at least 28 days (+3 days) after the first dose of study intervention (Day 29).

The primary objective of the study was to assess the proportion of participants alive and free of respiratory failure at Day 29.

03

Conditions studied

  • Coronavirus
  • COVID
  • ARDS
  • Cytokine Storm
  • Cytokine Release Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Type of Participant and Disease Characteristics -

  1. Documented or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by an FDA-approved polymerase chain reaction test of nasopharyngeal swab or stool less than 72 hours before randomization
  2. Hospitalized for COVID-19
  3. Illness of any duration with at least 1 of the following:

    1. Clinical assessment (evidence of rales/crackles on exam) and peripheral capillary oxygen saturation less than or equal to 94% on room air, or
    2. Requiring mechanical ventilation and/or supplemental oxygen, or
    3. Radiographic evidence (chest x-ray or computed tomography scan) of 1 of the following:

      • Ground-glass opacities, or
      • Local or bilateral patchy infiltrates, or
      • Interstitial pulmonary infiltrates
  4. If the participant was intubated, must have been intubated less than 24 hours prior to randomization

    Sex and Guidelines -

  5. Contraceptive use by men or women should have been consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    -

  6. Capable of giving signed informed consent or by a designated representative, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol

Exclusion criteria

Exclusion Criteria:

Medical Conditions -

  1. Active bacterial pneumonia defined: based on either lobar consolidation on x-ray, positive sputum cultures, or leukocytosis with a left shift
  2. Known active tuberculosis
  3. Participants with acquired immune deficiency syndrome
  4. It is not in the best interest of the participants to participate, in the opinion of the treating Investigator.
  5. In the opinion of the investigator, progression to death was imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
  6. Female participants who were pregnant or breastfeeding or expecting to conceive within the projected duration of the study, starting with the screening visit through 90 days after the last dose of study intervention

    Excluded Prior/Concomitant Therapy -

  7. Prior treatment with other agents with actual or possible direct acting anti-inflammatory activity against SARS-CoV-2 in the past 30 days (for example, chloroquine, hydroxychloroquine)
  8. Treatment with convalescent plasma
  9. Treatment with high doses of (greater than 20 milligrams daily, prednisone equivalent) prior to randomization
  10. Treatment with immunomodulators including anti-interleukin (IL)-6, anti-IL-6 receptor antagonists, or with Janus kinase inhibitors in the past 30 days or plans to receive during the study period
  11. Previous exposure to study intervention or any other agent targeting colony stimulating factor-1 or CSF-1R or known allergy/sensitivity to study intervention
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
1 participant (actual)

Study arms

  • Active comparator
    Axatilimab (SNDX-6352)

    Axatilimab on Days 1 and 15, IV + SOC

    Drug: SNDX-6352

  • Placebo comparator
    Placebo

    Matching placebo on Days 1 and 15, IV + SOC

    Drug: Placebo

Interventions

  • SNDX-6352

    Also known as: Axatilimab

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Count Of Participants Alive And Free Of Respiratory Failure At Day 29

    Respiratory failure was defined by need for mechanical ventilation, extracorporeal membrane oxygenation, non-invasive ventilation \>6 liters oxygen/minute, or clinical diagnosis of respiratory failure with initiation of none of these measures only when clinical decision-making was driven solely by resource limitation.

    Time frame: Day 29

Secondary outcomes

  1. Count Of Participants With Secondary Clinical Improvement Outcomes At Day 29

    Participants achieving a ≥2 category improvement on a 7-point ordinal score relative to the baseline on Day 28 as collected on Day 29 are reported.

    Time frame: Day 29

  2. Time To Clinical Improvement

    The time to clinical improvement is defined as a national early warning score of ≤2 maintained for 24 hours.

    Time frame: Baseline through Day29

  3. Change From Baseline At Day 29 In Oxygenation In Hospitalized Adults With Respiratory Signs And Symptoms Secondary To COVID-19 Treated With Axatilimab

    The change from baseline at Day 29 or hospital discharge or death, if sooner, in the ratio of peripheral hemoglobin oxygen saturation to fraction of inspired oxygen is evaluated.

    Time frame: Baseline, Day 29

  4. Change From Baseline At Day 15 In Biomarkers Following Treatment With Axatilimab

    The change from baseline at Day 15 in serum concentrations of interleukin 6 and c-reactive protein or hospital discharge or death is evaluated.

    Time frame: Baseline, Day 15

  5. Count Of Participants Experiencing Adverse Events And Serious Adverse Events

    This outcome measure evaluates the safety and tolerability of axatilimab within the same population. A summary of all serious adverse events and other adverse events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.

    Time frame: Baseline through Day 29

  6. Count Of Participants Requiring Ventilation Support

    Participants who required initiation of mechanical ventilation after study entry are analyzed.

    Time frame: Baseline through Day 29

  7. Count Of Participants Considered Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Free By Day 15

    This outcome measure evaluates the antiviral effects of axatilimab in hospitalized adults by Day 15 or hospital discharge, whichever was sooner, with recently diagnosed SARS-CoV-2 infection.

    Time frame: Day 15

  8. Pharmacokinetics: Serum Concentration Of Axatilimab And Anti-drug Antibodies

    The serum concentration of axatilimab and presence of anti-drug antibodies is evaluated.

    Time frame: Day 29

07

Results

Posted Jul 22, 2022
Limitations and caveats
This study was terminated by the Sponsor given enrollment challenges, partly attributable to the constantly changing COVID-19 treatment landscape. Due to study termination and only 1 participant being enrolled there are concerns regarding participant confidentiality, therefore no data are being reported.

Participant flow

Participant flow — Overall Study
MilestoneAxatilimab (SNDX-6352)Placebo
Started00
Completed00
Not completed00

Outcome measures

PrimaryCount Of Participants Alive And Free Of Respiratory Failure At Day 29

Respiratory failure was defined by need for mechanical ventilation, extracorporeal membrane oxygenation, non-invasive ventilation \>6 liters oxygen/minute, or clinical diagnosis of respiratory failure with initiation of none of these measures only when clinical decision-making was driven solely by resource limitation.

Time frame:
Day 29

No measurements were reported for this outcome.

SecondaryCount Of Participants With Secondary Clinical Improvement Outcomes At Day 29

Participants achieving a ≥2 category improvement on a 7-point ordinal score relative to the baseline on Day 28 as collected on Day 29 are reported.

Time frame:
Day 29

No measurements were reported for this outcome.

SecondaryTime To Clinical Improvement

The time to clinical improvement is defined as a national early warning score of ≤2 maintained for 24 hours.

Time frame:
Baseline through Day29

No measurements were reported for this outcome.

SecondaryChange From Baseline At Day 29 In Oxygenation In Hospitalized Adults With Respiratory Signs And Symptoms Secondary To COVID-19 Treated With Axatilimab

The change from baseline at Day 29 or hospital discharge or death, if sooner, in the ratio of peripheral hemoglobin oxygen saturation to fraction of inspired oxygen is evaluated.

Time frame:
Baseline, Day 29

No measurements were reported for this outcome.

SecondaryChange From Baseline At Day 15 In Biomarkers Following Treatment With Axatilimab

The change from baseline at Day 15 in serum concentrations of interleukin 6 and c-reactive protein or hospital discharge or death is evaluated.

Time frame:
Baseline, Day 15

No measurements were reported for this outcome.

SecondaryCount Of Participants Experiencing Adverse Events And Serious Adverse Events

This outcome measure evaluates the safety and tolerability of axatilimab within the same population. A summary of all serious adverse events and other adverse events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.

Time frame:
Baseline through Day 29

No measurements were reported for this outcome.

SecondaryCount Of Participants Requiring Ventilation Support

Participants who required initiation of mechanical ventilation after study entry are analyzed.

Time frame:
Baseline through Day 29

No measurements were reported for this outcome.

SecondaryCount Of Participants Considered Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Free By Day 15

This outcome measure evaluates the antiviral effects of axatilimab in hospitalized adults by Day 15 or hospital discharge, whichever was sooner, with recently diagnosed SARS-CoV-2 infection.

Time frame:
Day 15

No measurements were reported for this outcome.

SecondaryPharmacokinetics: Serum Concentration Of Axatilimab And Anti-drug Antibodies

The serum concentration of axatilimab and presence of anti-drug antibodies is evaluated.

Time frame:
Day 29

No measurements were reported for this outcome.

Adverse events

Collected over This study was terminated by the Sponsor. Due to study termination and only 1 participant being enrolled there are concerns regarding participant confidentiality, therefore no data are being reported.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axatilimab (SNDX-6352)———
Placebo———

Baseline characteristics

This study was terminated by the Sponsor. Due to study termination and only 1 participant being enrolled there are concerns regarding participant confidentiality, therefore no data are being reported.

Age, Continuous
Age, ContinuousAxatilimab (SNDX-6352)PlaceboTotal
Sex: Female, Male
Sex: Female, MaleAxatilimab (SNDX-6352)PlaceboTotal
Female———
Male———
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)Axatilimab (SNDX-6352)PlaceboTotal
Hispanic or Latino———
Not Hispanic or Latino———
Unknown or Not Reported———
Race (NIH/OMB)
Race (NIH/OMB)Axatilimab (SNDX-6352)PlaceboTotal
American Indian or Alaska Native———
Asian———
Native Hawaiian or Other Pacific Islander———
Black or African American———
White———
More than one race———
Unknown or Not Reported———
Region of Enrollment
Region of Enrollment(participants)Axatilimab (SNDX-6352)PlaceboTotal
08

Study locations

2 sites
  • HonorHealth
    Scottsdale, Arizona 85258, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
09

References and documents

Publications

  • Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. PubMed 34473343 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Jul 2020, 1 month.

Results were first posted in Jul 2022, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2020
First posted
Jun 4, 2020
StartActual
May 30, 2020
Primary completionActual
Jul 13, 2020
CompletionActual
Jul 13, 2020
Results first posted
Jul 22, 2022
Last update
Jul 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04415073
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
May 30, 2020
Primary completion
Jul 13, 2020
Completion
Jul 13, 2020
Results posted
Jul 22, 2022
Last update
Jul 22, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axatilimab

Start the discussion